Skip to content

Mindfulness-based Cognitive Therapy for Generalized Anxiety Disorder: A Preliminary Evaluation

Mark A. Craigie, Clare S. Rees, Ali Marsh, Paula Nathan

Behavioural and Cognitive Psychotherapy October 1, 2008 DOI: 10.1017/s135246580800458x (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Uncontrolled pre-post design Peer reviewed
Sample size 23
Population Adults with a primary diagnosis of generalized anxiety disorder (GAD)
Intervention Mindfulness-based cognitive therapy (MBCT)
Duration 9 weekly 2-hour group sessions, with post-treatment assessment and 6-week and 3-month follow-ups
Topics Anxiety Meditation
Key points MBCT significantly reduced pathological worry, stress, and other symptoms and improved quality of life at post-treatment, with gains maintained at follow-up; however, recovery rates based on standardized criteria were very small at post-treatment but improved by follow-up.

Abstract

Abstract Mindfulness training has been proposed as a potentially important new approach for the treatment of generalized anxiety disorder (GAD). However, to date only a few studies have investigated mindfulness training for GAD. The aim of this study was to further investigate symptom change and recovery in pathological worry after mindfulness-based cognitive therapy (MBCT) using an uncontrolled pre-post design. Twenty-three adults with a primary diagnosis of GAD participated in the study. The MBCT program involved 9 weekly 2-hour group sessions, a post-treatment assessment session, and 6-week and 3-month follow-up sessions. Intent-to-treat analysis revealed significant improvements in pathological worry, stress, quality of life, and a number of other symptoms at post-treatment, which were maintained at follow-up. Attrition was also low, and MBCT was perceived as a credible and acceptable intervention. However, when applying standardized recovery criteria to pathological worry scores, the rate of recovery at post-treatment was very small, although improved at follow-up. Overall, the findings suggest MBCT is definitely worthy of further investigation as a treatment option for GAD, but falls well short of outcomes achieved by past research. Possible reasons for the poor rate of recovery, implications, and limitations are briefly outlined.

Comparable studies

Other non-randomized and open-label trials on anxiety, most cited first.

Study Year Design Participants
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) 2006 Controlled clinical trial
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Emotions and brain function are altered up to one month after a single high dose of psilocybin. Healthy volunteers (7 female, 5 male) 2020 Open-label pilot study n = 12
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study Older long-term AIDS survivor (OLTAS) self-identified gay men with moderate-to-severe... 2020 Open-label study

Citations in the library

Explore topics